Comment from Raul Delgado
AnonymousOpposeIndividual
Summary: An individual commenter opposes the FDA's proposal to weaken safety protocols and remove Risk Evaluation and Mitigation Strategy (REMs) requirements for mifepristone. They argue that the drug poses significant risks to women's health and should be subject to strict regulation and robust safety measures.
To whom it may concern,
There is only one purpose for the persistence request to use the abortion drug mifepristone at the expense of more than one life - money. One’s callousness should not be tolerated and accepted in a civilized society. History has proven over and over again that a wrong does not a make right. Let us not continue this insanity and instead speak the truth – one’s life matters.
Therefore, I am strongly opposed to the FDA weakening safety protocols and removing the Risk Evaluation and Mitigation Strategy (REMs) safety requirements for the abortion drug mifepristone. Drugs with significant risks must be strictly regulated, and mifepristone is no exception. FDA data links this drug to at least 36 deaths and thousands of adverse events. A 2024 Ethics and Public Policy Center report found that 11% of chemical abortions resulted in adverse events.
When a drug poses such dangers to women’s health and lives, robust safety measures are essential. I urge the FDA to maintain—and strengthen—current safety protocols for mifepristone to protect women nationwide.
Signed,